Piper Jaffray Downgrades Salix Pharmaceuticals To Neutral

Analysts at Piper Jaffray downgraded Salix Pharmaceuticals Ltd. SLXP from Overweight to Neutral. The price target for Salix Pharmaceuticals has been lowered from $160.00 to $158.00. Salix Pharmaceuticals shares have gained 45.81% over the past 52 weeks, while the S&P 500 index has surged 14.22% in the same period. Salix Pharmaceuticals' shares fell 0.82% to $156.56 in pre-market trading.